Back | Next |
home / stock / snpx / snpx message board
Subject | By | Source | When |
---|---|---|---|
Any thoughts on TLSA/Foralumab? | redspinelpinktopaz | investorshub | 04/02/2023 2:35:29 PM |
Thanks for the links folks. That is interesting | runncoach | investorshub | 04/02/2023 1:34:55 PM |
That was an interesting finding from the studies. | Doc328 | investorshub | 04/02/2023 12:51:15 PM |
Brains Shrink With Anti-Amyloid Alzheimer's Drugs Treatments accelerate | Babaji | investorshub | 04/01/2023 2:52:51 PM |
At least they have the guts to put | runncoach | investorshub | 03/31/2023 5:57:34 PM |
Agreed... | XenaLives | investorshub | 03/31/2023 3:32:42 PM |
Company deserves a dignified death. Snake oil peddling | urge2surge | investorshub | 03/24/2023 1:18:34 AM |
Only approved drug so we'll have to see | runncoach | investorshub | 03/23/2023 12:08:34 AM |
Regarding Daybue it is still to be seen | Investor2014 | investorshub | 03/22/2023 11:58:26 PM |
Like most, you don't know until you get | runncoach | investorshub | 03/22/2023 11:54:37 PM |
I am not sure it ever did. longer term | Investor2014 | investorshub | 03/22/2023 11:42:13 PM |
Looks like some amendments to the money raise | runncoach | investorshub | 03/22/2023 11:17:27 PM |
10k filed. I don't have time to | runncoach | investorshub | 03/22/2023 11:37:19 AM |
Lol | runncoach | investorshub | 03/09/2023 3:36:47 PM |
There is no clear MOA even theorized for | XenaLives | investorshub | 03/09/2023 12:52:07 PM |
Yeah I would like to see the exact | runncoach | investorshub | 03/07/2023 6:01:55 PM |
It's not looking good. They have failed to | Cyosol | investorshub | 03/07/2023 5:31:39 PM |
Not going to happen is my guess. They | runncoach | investorshub | 03/07/2023 4:37:02 PM |
Plenty of statistically significant efficacy end points for | Babaji | investorshub | 03/07/2023 4:23:32 PM |
Snake oil and another attempt to spin a | urge2surge | investorshub | 03/07/2023 3:48:53 PM |
News, Short Squeeze, Breakout and More Instantly...
Synaptogenix Inc. Company Name:
SNPX Stock Symbol:
OTCMKTS Market:
Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis PR Newswire Collaborative study will evaluate drug's potential to improve synaptic health and cognitive function in MS patients NEW YORK , ...
Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery PR Newswire Proposed Schedule III drug classification expected to de-risk Cannasoul's cannabis research and potential regulatory pathways ...